Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Rebecca Perrett.

Newcastle AuthorsTitleYearFull text
Professor Ruth Plummer
Rebecca Perrett
Professor Alan Calvert
A phase I and pharmacokinetic (PK) study of BIBW 2992, an oral irreversible dual EGFR/HER2 inhibitor2007
Professor Alan Calvert
Dr Fathi Azribi
Rebecca Perrett
Professor Ruth Plummer
Activity of BIBW2992, an oral irreversible dual EGFR/HER2 inhibitor, in non-small cell lung cancer (NSCLC) with mutated EGFR2007
Dr Graham Dark
Rebecca Perrett
Deconstructing the construction of a learning module on practice development2007
Professor Ruth Plummer
Dr Louise Li
Rebecca Perrett
Professor Alan Calvert
Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers2007
Dr Graham Dark
Rebecca Perrett
Practice development - Part 1: Developing a practice initiative in oncology and palliative care2007
Dr Graham Dark
Rebecca Perrett
Practice development - Part 2: evaluating a practice initiative2007
Dr Graham Dark
Rebecca Perrett
Using e-learning as a tool for multidisciplinary education2007
Professor Ruth Plummer
Rebecca Perrett
Professor Alan Calvert
A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in patients with advanced solid tumours2006
Professor Ruth Plummer
Dr Louise Li
Rebecca Perrett
Professor Alan Calvert
Phase I study of BIBW2992, an oral irreversible dual EGFR/HER2 inhibitor, showing activity in tumours with mutated EGFR2006
Professor Ruth Plummer
Rebecca Perrett
Professor Alan Calvert
A phase 1 dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumors2005